SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 32.51+0.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: grannylu who wrote (249)8/19/1998 8:23:00 AM
From: Harold Engstrom   of 340
 
If you had read my post accurately, you would have read that Avonex has a far better side-effect profile than COP-1. And has proven to an FDA board that it is the ONLY MS treatment to slow progression of the disease. That is FACT. Teva's data has not passed FDA scrutiny and achieved a labelling that corresponds to the claims the company's own studies supposedly show. As far as I know, Teva's studies were not rigorous clinical trials - they were "studies" paid for by the company. I could be wrong, but this is my interpretation of the company's own press releases.

As I said in my previous post, not every patient responds to every treatment equally. If you do have a daughter with MS, she is lucky to have a choice of treatments.

I bought into Teva at 32-7/8 3 weeks ago.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News